ABERDEEN, Scotland and Singapore, 16th November 2016 – Following presentation of top-line results from its TRx-237-015 Phase 3 clinical trial in Alzheimer’s disease at the 2016 Alzheimer’s Association International Conference (AAIC) in Toronto, Canada in July, TauRx today confirms publication of the full study results in The Lancet.1
In this publication, the study authors describe the efficacy and safety of the first tau-aggregation inhibitor therapy in this population with mild or moderate Alzheimer’s disease.
Read more here.
TRx-237-015 Phase 3 clinical trial published in The Lancet
Following presentation of top-line results from its TRx-237-015 Phase 3 clinical trial in Alzheimer’s disease at the 2016 AAIC, TauRx confirms publication of the full study results in The Lancet.
